rct
    2014
    High Quality

    Mesalamine does not prevent recurrent diverticulitis in phase 3 controlled trials (PREVENT)

    Raskin JB, Kamm MA, Jamal MM

    Published in Gastroenterology

    Methodology

    Two identical phase 3 randomized, double-blind, placebo-controlled trials of mesalamine for prevention of recurrent diverticulitis.

    Key Findings

    Mesalamine did not reduce diverticulitis recurrence compared with placebo in either trial.

    Conclusions

    Maintenance anti-inflammatory therapy is not effective for recurrent diverticulitis.

    Limitations

    Recurrence defined by imaging-confirmed criteria only.

    Related Health Concerns

    Diverticulitis

    Study Details

    Year:2014
    Sample Size:1,182
    Duration:104 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.